Application No.: 09/816,839 Attorney Docket No.: TNX 00-04

Customer No.: 26839

## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claims 1-18 (Canceled)

- 19. (Previously Amended) An antibody that binds to C2a or the C2a portion of C2, or a C2a binding fragment thereof, which inhibits complement activation more than 50% at a molar ratio of 1:2 (antibody to C2).
- 20. (Currently Amended) An antibody that binds to C2a or the C2a portion of C2, or a C2a binding fragment thereof, which inhibits both the classical and the lectin complement pathways more than 50% at a molar ratio of about-1:2 (antibody to C2).
- 21. (Canceled)
- 22. (Previously Presented) The antibody of claim 19, wherein the antibody fragment is a Fab, F(ab')<sub>2</sub>, Fv or single chain Fv.
- 23. (Previously Presented) The antibody of claim 19, wherein the antibody is monoclonal.
- 24. (Previously Presented) The monoclonal antibody of claim 23, wherein the antibody is a chimeric, deimmunized, humanized or a human antibody.
- (Currently Amended) A monoclonal antibody <u>produced by hybridoma cell line</u>
  175-62 <u>and deposited under ATCC Accession Number PTA-1553.</u>
- 26. (Currently Amended) A cell line that produces the monoclonal antibody designated 175-62 deposited under ATCC Accession No. PTA-1553.

Application No.: 09/816,839 Attorney Docket No.: TNX 00-04

Customer No.: 26839

- 27. (Currently Amended) A pharmaceutical composition comprising the antibody of claim 19 and a pharmacologically acceptable carrier, excipient, stabilizer, or diluent.
- 28. (Previously Amended) A method of inhibiting complement activation comprising administering the antibody of claim 19 or claim 20.
- 29. (Previously Amended) A method of inhibiting the classical and lectin complement pathways comprising administering the antibody of claim 19 or claim 20.
- 30. (Previously Presented) The method of claim 28, wherein the inhibition of complement activation is determined *in vitro*.
- 31. Canceled
- 32. (Previously Amended) A method of treating a disease or condition that is mediated by excessive or uncontrolled activation of the complement system comprising administering, in vivo or ex vivo, the antibody of claim 19 or claim 20.
- 33. (Previously Presented) The method of claim 32, wherein the antibody is administered by intravenous infusion, intravenous bolus injection, intraperitoneal, intradermal, intramuscular, subcutaneous, intranasal, intratracheal, intraspinal, intracranial, or orally.
- 34. (Previously Presented) A diagnostic method comprising the detection of the amount of C2 or C2a present in a sample with the antibody of claim 19.
- 35. (Currently Amended) The diagnostic method of claim 34, wherein the antibody is the monoclonal antibody designated 175-62 and deposited under ATCC Accession number PTA-1553.

Application No.: 09/816,839 Attorney Docket No.: TNX 00-04

Customer No.: 26839

- 36. (NEW) An antibody that binds to C2a or the C2a portion of C2, or a C2a binding fragment thereof, which completely inhibits complement activation at a molar ratio of 1:2 (antibody to C2).
- 37. (NEW) The antibody of claim 36, wherein the antibody is a monoclonal antibody produced by hybridoma cell line 175-62 and deposited under ATCC Accession Number PTA-1553.